Tarsus Pharmaceuticals, Inc. (TARS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Irvine, CA, United States. El CEO actual es Bobak R. Azamian.
TARS tiene fecha de IPO 2020-10-16, 323 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $3.14B.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Irvine, California, focused on developing novel therapeutic candidates for ophthalmic and dermatological conditions. The company's lead product candidate, TP-03, is in Phase III clinical trials for treating blepharitis caused by Demodex mite infestation and meibomian gland disease. Tarsus is also advancing a pipeline that includes TP-04 for rosacea treatment and TP-05 for Lyme disease prophylaxis and malaria reduction, alongside the development of lotilaner for multiple therapeutic applications across ophthalmology, dermatology, and other disease areas. Founded in 2016, the company is positioned to address significant unmet medical needs in eye care and skin conditions.
